ARICLAIM 60 mg hard gastro-resistant capsules

ATC Code
N06AX21
Medikamio Hero Image

Eli Lilly Nederland B.V.

Substance Narcotic Psychotropic
Duloxetine No No
Pharmacological group Antidepressants

Ad

All to know

Author

Eli Lilly Nederland B.V.

What is it?

Ariclaim is a medicine that contains the active substance duloxetine. It is available as gastroresistant capsules (white and blue: 30 mg; green and blue: 60 mg). ?Gastroresistant? means that the capsules? contents pass through the stomach without being broken down until they reach the intestine. This prevents the active substance being destroyed by the acid in the stomach.

What is it used for?

Ariclaim is used to treat pain due to diabetic peripheral neuropathy (damage to the nerves in the extremities that can occur in patients with diabetes).
The medicine can only be obtained with a prescription.

Ad

How is it used?

The recommended dose of Ariclaim is 60 mg once a day, but some patients may need a higher dose of 120 mg per day. The response to treatment should be assessed two months after starting treatment. If the treatment is effective, it should then be evaluated at least every three months. Ariclaim can be taken with or without food. The dose should be reduced gradually when stopping treatment.

How does it work?

The active substance in Ariclaim, duloxetine, is a serotonin-noradrenaline re-uptake inhibitor. It works by preventing the neurotransmitters 5-hydroxytrypamine (also called serotonin) and noradrenaline from being taken back up into nerve cells in the brain and spinal cord. Neurotransmitters are chemicals that allow nerve cells to communicate with one another. By blocking their re-uptake, duloxetine increases the amount of these neurotransmitters in the spaces between these nerve cells, increasing the level of communication between the cells. Since these neurotransmitters are involved in reducing the sensation of pain, blocking their re-uptake into nerve cells may improve the symptoms of neuropathic pain.

How has it been studied?

Ariclaim has been studied in two 12-week studies in 809 diabetic adults who had had pain every day for at least six months. Three different doses of Ariclaim were compared with placebo. The main measure of effectiveness was the change in the severity of pain each week, as recorded by the patients on an 11-point scale in daily diaries.

What benefits has it shown during the studies?

Ariclaim at doses of 60 mg once or twice a day was more effective at reducing pain than placebo. In both studies, pain reduction was seen from the first week of treatment for up to 12 weeks, with patients taking Ariclaim having pain scores between 1.17 and 1.45 points lower than those taking placebo.

What is the risk associated?

The most common side effects with Ariclaim (seen in more than 1 patient 10) are headache, somnolence (sleepiness), dizziness, nausea and dry mouth. Most of these were mild or moderate, starting early in treatment and getting milder as treatment continued. For the full list of all side effects reported with Ariclaim, see the Package Leaflet.
Ariclaim should not be used in people who may be hypersensitive (allergic) to duloxetine or any of the other ingredients. Ariclaim must not be used in patients with certain types of liver disease or with severe kidney disease. It must not be used together with monoamine oxidase inhibitors (a group of antidepressants), fluvoxamine (another antidepressant), or ciprofloxacin or enoxacin (types of antibiotic). Treatment must not be started in patients with uncontrolled high blood pressure, because of a risk of hypertensive crisis (sudden, dangerously high blood pressure).

Why has it been approved?

The Committee for Medicinal Products for Human Use (CHMP) decided that Ariclaim?s benefits are greater than its risks for the treatment of diabetic peripheral neuropathic pain in adults. The Committee recommended that Ariclaim be given marketing authorisation.
Ariclaim was originally also authorised at strengths of 20 and 40 mg for the treatment of moderate to severe stress urinary incontinence (SUI) in women, but the company withdrew these strengths when the marketing authorisation was renewed in August 2009. SUI is accidental leaks of urine during physical exertion or when coughing, laughing, sneezing, lifting or exercising.

Your personal medicine assistent

Drugs

Search our database for drugs, sorted from A-Z with their effects and ingredients.

Substances

All substances with their common uses, chemical components and medical products which contain them.

The contents shown do not replace the original package insert of the medicinal product, especially with regard to dosage and effect of the individual products. We cannot assume any liability for the correctness of the data, as the data was partly converted automatically. A doctor should always be consulted for diagnoses and other health questions. Further information on this topic can be found here.

This website is certified by Health On the Net Foundation. Click to verify.